AbCellera Biologics : Corporate Overview

Published: 2025-05-18 20:06:48 ET ABCL

Published on 05/18/2025 at 20:06

May 2025

TECHNOLOGY

AbCellera is an early stage biotech with integrated capabilities for

TEAM

Corporate Overview

PLATFORM

Our platform combines computation, engineering, molecular design, and biology to support the discovery, development, and clinical manufacturing of differentiated antibody therapies, from target to the clinic.

INFRASTRUCTURE

STRATEGY

Corporate Overview

Build a competitive advantage

Investments in technological capability can improve the productivity of drug development.

So you can solve hard problems

Long-term value creation comes from being able to repeatedly deliver ﬁrst-in-class and best-in-class medicines.

Corporate Overview

Our engine was built through 10 years of drug discovery partnerships.

Since 2014, we have partnered with some of the industry's most innovative pharma and biotech companies. Partnerships were a driver for R&D, and provided near-term revenue in the form of research payments and long-term potential revenue in the form of royalty stakes in those drug programs.

In 2023, we shifted our focus from partnerships to advancing a pipeline of internal and co-developed programs.

partnered-initiated therapeutic programs*

molecules from partnered programs have reached the clinic*

AbbVie

*As of December 31, 2024

Disclaimer

Abcellera Biologics Inc. published this content on May 18, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 19, 2025 at 00:05 UTC.